FDA panel backs Glaxo Wellcome drug for use in treating chronic hepatitis B. Food and Drug Administration.
D000998:Antiviral Agents / Q000627:therapeutic use*; D017277:Drug Approval; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D019259:Lamivudine